The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...

For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...

BridgeBio Oncology Therapeutics, which was spun out of BridgeBio Pharma (NASDAQ:BBIO) last year, has agreed to merge with Helix Acquisition Corp. II (NASDAQ:HLXB), a Boston-headquartered SPAC, to ...

We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going ...

BofA raised the firm’s price target on BridgeBio (BBIO) to $46 from $45 and keeps a Buy rating on the shares after accounting for the updated ...

Prescription totals for Attruby, which is locked in a closely watched commercial battle with Pfizer’s tafamidis, have more ...

Refinancing term debt facility lowers interest expense, eliminates near-term amortization payments, and significantly extends ...

But the direct-to-consumer ad didn't come from Palo Alto-based Bridge Bio (Nasdaq: BBIO); instead it was produced by Pfizer ...

One year after its initial public offering, Helix Acquisition Corp. II is now helping another biotech company go public.

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the firm, MarketBeat.com reports ...

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its price target lifted by Citigroup from $45.00 to $49.00 in a research ...

Long term debt management strategy will strengthen the balance sheet without increasing total liabilities - Refinancing term ...